US2017105948A1PendingUtilityA1

Nutritional compositions for modulating inflammation including exogenous vitamin k2

Assignee: NESTEC SAPriority: Sep 14, 2009Filed: Dec 23, 2016Published: Apr 20, 2017
Est. expirySep 14, 2029(~3.1 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 37/08A61P 5/26A61P 25/00A61P 3/02A61P 29/02A61P 29/00A61P 19/08A61P 1/00A61P 21/00A61P 1/04A61P 19/00A61P 13/12A23L 33/10A23L 2/52A23L 33/175A61K 31/122A61K 33/26A23L 33/135A61K 33/06A61K 33/30A23V 2002/00A61K 31/593A23L 33/15A61K 33/32C12Q 2600/106A61K 33/42A23L 33/16C12Q 1/6883A61K 33/00A61K 45/06A61K 33/34A23L 33/40
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, a nutritional composition includes exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.

Claims

exact text as granted — not AI-modified
The invention is claimed as follows: 
     
         1 . A method of modulating the effects of inflammation, the method comprising:
 administering a nutritional composition comprising an effective amount of exogenous vitamin K 2  to a patient having at least one condition selected from the group consisting of developmental delay, failure-to-thrive, Crohn's disease, Crohn's Disease-associated osteopenia, colitis, ulcerative colitis, celiac disease, gluten intolerance, neuromuscular dysfunction, renal dysfunction, androgen deficiency, severe food allergy, short bowel syndrome, and combinations thereof.   
     
     
         2 . The method of  claim 1  wherein the exogenous vitamin K2 is selected from the group consisting of MK-4, MK-7 and combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the exogenous vitamin K2 is MK-7. 
     
     
         4 . The method of  claim 1 , wherein the effective amount of exogenous vitamin K2 is from about 1 μg to about 100 μg per day. 
     
     
         5 . The method of  claim 1 , wherein the effective amount of exogenous vitamin K2 is from about 20 μg to about 90 μg per day. 
     
     
         6 . The method of  claim 1 , wherein the effective amount of exogenous vitamin K2 is from about 50 μg to about 80 μg per day. 
     
     
         7 . The method of  claim 1 , wherein the nutritional composition is in an administrable form selected from the group consisting of pharmaceutical formulations, nutritional formulations, tube-feed formulations, dietary supplements, functional foods and beverage products. 
     
     
         8 . The method of  claim 1 , the nutritional composition further comprising at least one component selected from the group consisting of prebiotic, probiotics, symbiotic, amino acid, protein, nucleotides, a fish oil, non-marine omega-3 fatty acid containing dietary fat source, phytonutrients, antioxidant, and combinations thereof. 
     
     
         9 . The nutritional composition of  claim 8 , wherein the amino acid is selected from the group consisting of proline, hydroxyproline, hydroxytyrosine, hydroxylysine and hydroxyserine and combinations thereof. 
     
     
         10 . The method of  claim 1 , wherein the modulation of the effects of inflammation is a reducing of the effects of inflammation. 
     
     
         11 . The method of  claim 1 , wherein the modulation of the effects of inflammation is a preventing of the effects of inflammation. 
     
     
         12 . The method of  claim 1 , wherein the modulation of the effects of inflammation is decreasing a rise of plasma TNF-α under conditions of inflammation. 
     
     
         13 . The method of  claim 1 , wherein the modulation of the effects of inflammation is blunting a drop in phosphorylation for IKKα/β and NFκB p65 induction under conditions of inflammation. 
     
     
         14 . The method of  claim 1 , wherein the modulation of the effects of inflammation is abrogating a decrease in 4E-BP1(Thr-37) and ribosomal protein S6 phosphorylation under conditions of inflammation. 
     
     
         15 . The method of  claim 1 , wherein the modulation of the effects of inflammation is preserving the fractional rate of mixed muscle protein synthesis under conditions of inflammation. 
     
     
         16 . The method of  claim 1 , wherein the patient is a child.

Join the waitlist — get patent alerts

Track US2017105948A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.